Aerie Pharmaceuticals Revenue 2011-2026 | AERI

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Aerie Pharmaceuticals

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
194 M	83.1 M	69.9 M	24.2 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
194 M	24.2 M	92.8 M

Quarterly Revenue Aerie Pharmaceuticals

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	29.8 M	-	29.3 M	27.2 M	23 M	24.7 M	20.1 M	18 M	20.3 M	24.7 M	18.5 M	15.8 M	10.9 M	14.5 M	7.3 M	2.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
29.8 M	2.42 M	19.1 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Drug manufacturers industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
AcelRx Pharmaceuticals ACRX	28 K	-	7.5 %	$ 6.35 M	USA
Alimera Sciences ALIM	80.8 M	-	-	$ 142 M	USA
Agile Therapeutics AGRX	19.6 M	-	10.11 %	$ 58.2 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.76 M	-	0.86 %	$ 117 M	USA
China Pharma Holdings CPHI	4.53 M	$ 0.57	-9.62 %	$ 9.95 M	China
Eagle Pharmaceuticals EGRX	317 M	-	-39.89 %	$ 27.7 M	USA
Aurora Cannabis ACB	175 M	$ 3.32	0.3 %	$ 86.3 M	Canada
Catalent CTLT	4.38 B	-	-	$ 11.5 B	USA
Athenex ATNX	103 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	169 M	-	-	$ 2.06 B	France
Cronos Group CRON	46.7 M	$ 2.58	2.38 %	$ 1.34 B	Canada
DURECT Corporation DRRX	8.55 M	-	-	$ 50.1 M	USA
Emergent BioSolutions EBS	1.05 B	$ 8.01	-0.5 %	$ 410 M	USA
Endo International plc ENDP	2.01 B	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	5.18 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	874 K	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	191 M	-	2.45 %	$ 38.1 M	Canada
Cumberland Pharmaceuticals CPIX	10.4 M	$ 3.13	2.62 %	$ 44 M	USA
Neoleukin Therapeutics NLTX	925 K	-	-	$ 193 M	Canada
Bausch Health Companies BHC	8.76 B	$ 4.99	-2.25 %	$ 1.82 B	Canada
Pacira BioSciences PCRX	542 M	$ 23.2	2.43 %	$ 1.07 B	USA
Harrow Health HROW	272 M	$ 35.2	3.53 %	$ 1.29 B	USA
PetIQ PETQ	1.1 B	-	1.64 %	$ 400 M	USA
OptiNose OPTN	71 M	-	-	$ 1.08 B	USA
PLx Pharma PLXP	8.21 M	-	-27.8 %	$ 2.56 M	USA
Perrigo Company plc PRGO	4.25 B	$ 9.64	0.73 %	$ 1.34 B	USA
ProPhase Labs PRPH	123 M	-	-	$ 5.07 M	USA
Evolus EOLS	297 M	$ 4.43	-5.34 %	$ 286 M	USA
Radius Health RDUS	230 M	-	-	$ 1.42 B	USA
Sundial Growers SNDL	946 M	$ 1.37	0.74 %	$ 3.37 M	Canada
Rockwell Medical RMTI	83.6 M	$ 1.03	0.98 %	$ 24 M	USA
Relmada Therapeutics RLMD	5.13 K	$ 6.1	4.1 %	$ 241 M	USA
OrganiGram Holdings OGI	160 M	$ 1.34	-1.47 %	$ 402 M	Canada
SCYNEXIS SCYX	20.6 M	$ 0.9	2.8 %	$ 44.9 M	USA
Jupiter Wellness JUPW	702 K	-	-	$ 33.6 M	USA
Lannett Company LCI	341 M	-	1.15 %	$ 7.11 M	USA
Sonoma Pharmaceuticals SNOA	14.3 M	$ 2.34	-8.24 %	$ 2.9 M	USA
Organogenesis Holdings ORGO	482 M	$ 2.41	-2.43 %	$ 317 M	USA
Canopy Growth Corporation CGC	269 M	$ 0.96	-0.87 %	$ 103 M	Canada
Tilray TLRY	627 M	$ 6.66	3.26 %	$ 4.12 B	Canada
Assertio Holdings ASRT	119 M	$ 16.51	17.93 %	$ 106 M	USA
TherapeuticsMD TXMD	1.3 M	$ 2.29	-0.87 %	$ 23.9 M	USA
Recro Pharma REPH	94.6 M	-	-4.76 %	$ 65.3 M	USA
Veru VERU	16.9 M	$ 2.29	-0.43 %	$ 309 M	USA
Viatris VTRS	15.4 B	$ 13.36	0.53 %	$ 16 B	USA
cbdMD YCBD	19.5 M	$ 0.77	1.06 %	$ 3.32 M	USA
Zynerba Pharmaceuticals ZYNE	86 K	-	-	$ 55.5 M	USA